Visioneering Technologies (VTI) is stepping up efforts to broaden its profile both geographically and through new product reach with the appointment of Kuang-mon (Ashley) Tuan, OD, PhD, FAAO, as Chief Medical Officer.
The US-based medical device company and producer of the NaturalVue Multifocal 1 Day contact lenses said Dr Tuan will be responsible for managing clinical research studies, such as Project PROTECT, the NaturalVue (etafilcon A) multifocal randomised clinical trial for myopia progression control in children; helping identify and develop new products; and leading efforts to communicate findings in key journals and scientific meetings.
Dr Tuan will also lead VTI’s Professional Services team as it communicates technical information on products and initiatives to eye care professionals.
Dr Tuan’s professional career encompasses 27 years’ experience and includes a strong background in clinical and vision research in areas such as myopia, higher order aberrations, presbyopia, refractive surgeries and age-related macular degeneration. Most recently, as Vice-President of Mojo Vision, a smart contact lens company, Dr Tuan focused on medical use cases and contact lens platform product strategy, and contact lens system research and development with oversight of clinical, regulatory, medical and professional affairs. While at CooperVision, Dr Tuan was part of the team that delivered the three-year study that enabled the launch of the myopia control contact lens, MiSight.
Dr Tuan said she is looking forward to “delivering solutions for the vision care community with the goal of reducing the risk of myopia-related visual impairment globally”.
